# Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

> **NCT00003525** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 8 (actual)

## Conditions studied

- Cervical Cancer Stage IV
- Vulvar Cancer, Stage IV

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003525
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-06-03
- **Primary completion:** 1998-01-22
- **Final completion:** 1998-01-22
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2017-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003525, "Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*